Viracta Therapeutics, Inc.
(NASDAQ : SNSS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 7.68%161.380.0%$1898.51m
OCGNOcugen, Inc. 6.32%8.750.0%$1079.84m
BNTXBioNTech SE 6.63%192.770.0%$872.52m
AMGNAmgen, Inc. 0.43%251.381.3%$740.91m
NVAXNovavax, Inc. 8.84%131.6979.8%$572.50m
SNSSSunesis Pharmaceuticals, Inc. 0.26%7.680.7%$536.86m
GILDGilead Sciences, Inc. -0.55%68.531.0%$504.56m
REGNRegeneron Pharmaceuticals, Inc. -0.11%516.622.7%$432.65m
ALXNAlexion Pharmaceuticals, Inc. 0.09%173.492.0%$412.31m
VRTXVertex Pharmaceuticals, Inc. 1.28%217.091.9%$311.54m
ILMNIllumina, Inc. 2.03%381.033.5%$302.74m
BIIBBiogen, Inc. -0.53%280.211.7%$269.43m
VXRTVaxart, Inc. 4.92%6.610.0%$240.79m
CRSPCRISPR Therapeutics AG 5.58%106.640.6%$171.41m
BNGOBionano Genomics, Inc. 22.45%5.400.0%$162.77m

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.